Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Novel selectin inhibitors revealed in the patent literature by Sumitomo

Aug. 2, 1999

Amgen discloses new class of cytokine production inhibitors

July 30, 1999

Aryl ureas for cytokine- and MMP-mediated conditions disclosed by Bayer

July 30, 1999

Cytokine production inhibitors from SB particularly useful for inflammation, osteoporosis

July 27, 1999

Fujisawa initiates enrollment in phase III RA trial of Prograf

July 27, 1999

Fungal metabolites useful as IL-1/TNF production inhibitors

July 23, 1999

P2X7 receptor antagonists for inflammatory, immune and cardiovascular disorders

July 23, 1999

Licensing opportunity from NIH: broad-spectrum chemokine antagonist

July 22, 1999

Amgen reveals latest in inhibitors of matrix metalloproteinases

July 21, 1999

New Amgen compounds for disorders mediated by TNF-alpha, collagenase and/or stromelysin

July 20, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
Other news to note for May 1, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: AC Immune, Aptose, Astrazeneca, Bioreference Health, Cardioline,...